Another July, another chance to recall that the Declaration of Independence exalted, among other things, the pursuit of happiness. For many, the pursuit can be circuitous but still, ultimately, rewarding. Consider single-cell RNA sequencing (scRNA-seq), which typically requires specialized instrumentation and consumables in addition to a sequencer, effectively disenfranchising many laboratories. But as this issue of GEN reports, kits are emerging that promise to democratize scRNA-seq, which is only fitting, since the technology expresses the “one cell, one vote” principle. This issue of GEN also includes an article describing how synthetic DNA production may be liberated an exclusive reliance on traditional methods now that enzymatic methods are being introduced. And several articles describe development platforms and manufacturing systems that are designed to ensure that the greatest number of patients will benefit from cell and gene therapies. Finally, despite our egalitarian impulses, we present a list of top 10 drugs.